news

SANY and Pony.ai Announce Mass-Production Readiness of Fourth-Generation Autonomous Heavy-Duty Truck

BEIJING, Dec. 8, 2025 /PRNewswire/ -- SANY Group announced that the fourth-generation autonomous heavy-duty truck co-developed by SANY Heavy Truck…

4 months ago

Numeros Motors Ditches Surveys for ‘Voicebox’, Capturing Unfiltered Customer Insights for n-First Launch

BENGALURU, India, Dec. 8, 2025 /PRNewswire/ -- Voicebox (vbx.ai), the enterprise platform transforming how brands capture customer sentiment, today announced…

4 months ago

Riyadh Air and IBM Partner to Launch World’s First AI-Native Airline

Riyadh Air's AI‑powered operations create agility across the business and unify employee and guest experiences, setting a new benchmark in…

4 months ago

Servier’s Voranigo (vorasidenib) Receives Prix Galien Awards Across Multiple Regions

Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product…

4 months ago

Allison Worldwide Expands Global Leadership with New Europe CEO

Former Hotwire UK CEO and Edelman MD Jeremy Lucas to turbocharge Allison's European capabilitiesLONDON, Dec. 8, 2025 /PRNewswire/ -- Allison…

4 months ago

Global Stars Confirmed as the Games of the Future Abu Dhabi 2025 Finalises Full Line-Up

Some of the biggest names in phygital sports and esports from around the world will head to Abu Dhabi for…

4 months ago

The 4th China International Supply Chain Expo Set for Beijing in June 2026

Sustained Worldwide Outreach Drives Greater Collaboration OpportunitiesBEIJING, Dec. 7, 2025 /PRNewswire/ --  The 4th China International Supply Chain Expo ("CISCE,"…

4 months ago

Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial…

4 months ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…

4 months ago

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

December 07, 2025 16:00 ET  | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) --…

4 months ago